<div id="readability-page-1">04:38 AM EST, 11/26/2025 (MT Newswires) -- Nyxoah SA ( NYXH ) said Wednesday that the US Centers for Medicare &amp; Medicaid Services has approved a new reimbursement rule, increasing the reimbursement rate applicable to the company's Genio neurostimulation therapy for obstructive sleep apnea.Effective Jan. 1, 2026, hospital outpatient department reimbursement for the code applicable to Genio will rise 48% to $45,000, while ambulatory surgery centers facility reimbursement will increase 58% to $42,373, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

NYXH

Nyxoah SA 宣布，美国医疗保险和医疗补助服务中心已批准一项新规则，提高其用于治疗阻塞性睡眠呼吸暂停的 Genio 神经刺激疗法的报销率。从 2026 年 1 月 1 日起，医院门诊部门的报销将增加 48%，达到 45,000 美元，而门诊手术中心的设施报销将增加 58%，达到 42,373 美元

Nyxoah 在新的 CMS 规则下获得了对 Genio 疗法的更高报销框架